Anavex Life Sciences (AVXL) News Today $9.27 -0.25 (-2.63%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$9.49 +0.22 (+2.37%) As of 10/10/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care’October 10 at 11:03 AM | markets.businessinsider.comAnavex Life Sciences Corp. Announces Oral Presentation on Alzheimer's Disease Care at Alzheimer Europe ConferenceOctober 10 at 7:50 AM | quiverquant.comQAnavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference ‘Connecting Science and Communities: The Future of Dementia Care'October 10 at 7:30 AM | globenewswire.comAnavex Life Sciences' (AVXL) "Buy" Rating Reiterated at HC WainwrightOctober 10 at 2:39 AM | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Given "Sell (D-)" Rating at Weiss RatingsOctober 8, 2025 | marketbeat.comHC Wainwright & Co. Reiterates Anavex Life Sciences (AVXL) Buy RecommendationOctober 8, 2025 | msn.comAnavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC WainwrightOctober 7, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Trading Up 8.7% - Should You Buy?October 3, 2025 | marketbeat.comAnavex rises after mid-stage trial data for schizophrenia candidateOctober 3, 2025 | msn.comAnavex rises after trial data for schizophrenia candidate (update)October 2, 2025 | msn.comAnavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important UpdateOctober 2, 2025 | msn.comAnavex: ANAVEX 3-71 Could Potentially Offer Disease-Modifying Effects For SchizophreniaOctober 2, 2025 | seekingalpha.comAnavex Life Sciences (NASDAQ:AVXL) Sees Strong Trading Volume - What's Next?October 2, 2025 | marketbeat.comAnavex Life Sciences Reports Positive Phase 2 Results for ANAVEX®3-71 in Schizophrenia Clinical Study Achieving Safety and Tolerability EndpointsOctober 2, 2025 | quiverquant.comQAnavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 ProgramOctober 2, 2025 | globenewswire.comAnavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaOctober 2, 2025 | globenewswire.comD. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy RecommendationOctober 1, 2025 | msn.comD. Boral Capital Maintains Anavex Life Sciences (AVXL) Buy RecommendationOctober 1, 2025 | msn.comAnavex Life Sciences (NASDAQ:AVXL) Earns "Buy" Rating from D. Boral CapitalOctober 1, 2025 | marketbeat.comAnavex announces publication on oral blarcamesine Phase IIb/III trialSeptember 30, 2025 | msn.comAnavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer’s Disease TrialSeptember 30, 2025 | markets.businessinsider.comAnavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease TrialSeptember 30, 2025 | globenewswire.comH.C. Wainwright Reiterates Its ‘Buy’ Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price TargetSeptember 24, 2025 | insidermonkey.comGoldman Sachs Group Inc. Reduces Stake in Anavex Life Sciences Corp. $AVXLSeptember 19, 2025 | marketbeat.comAnavex Life Sciences Earnings Call: Promising Alzheimer’s Progress Amid Operational ChallengesSeptember 13, 2025 | theglobeandmail.comAnavex Life Sciences (NASDAQ:AVXL) Trading Down 4.8% - Here's What HappenedSeptember 12, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC WainwrightSeptember 12, 2025 | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for Anavex Life Sciences (NASDAQ:AVXL)September 12, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Stock Price Up 9% - Here's What HappenedSeptember 11, 2025 | marketbeat.comAnavex Life Sciences Corp.: Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data ...September 9, 2025 | finanznachrichten.deAnavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In StudySeptember 9, 2025 | msn.comAnavex announces latest findings for blarcamesineSeptember 9, 2025 | msn.comAnavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer ...September 9, 2025 | markets.businessinsider.comAnavex Life Sciences out with New Drug to Fight Effects of AgingSeptember 9, 2025 | baystreet.caAnavex Life Sciences Reports Groundbreaking 48-Week Cognitive Stability Results for Blarcamesine in Early Alzheimer's Disease TreatmentSeptember 9, 2025 | quiverquant.comQAnavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease TrialSeptember 9, 2025 | globenewswire.comRafferty Asset Management LLC Buys 52,853 Shares of Anavex Life Sciences Corp. $AVXLSeptember 3, 2025 | marketbeat.comAnavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025September 2, 2025 | globenewswire.comAnavex Life Sciences Corp. $AVXL Position Boosted by Wellington Management Group LLPSeptember 2, 2025 | marketbeat.comNuveen LLC Purchases Shares of 189,041 Anavex Life Sciences Corp. $AVXLSeptember 1, 2025 | marketbeat.comInvesco Ltd. Sells 60,694 Shares of Anavex Life Sciences Corp. $AVXLAugust 30, 2025 | marketbeat.comAnavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral CapitalAugust 29, 2025 | marketbeat.comVanguard Group Inc. Acquires 221,802 Shares of Anavex Life Sciences Corp. $AVXLAugust 29, 2025 | marketbeat.comSwiss National Bank Invests $1.41 Million in Anavex Life Sciences Corp. $AVXLAugust 28, 2025 | marketbeat.comAnavex Life Sciences Reports Peer-Reviewed Publication on Blarcamesine's Mechanism in Autophagy Restoration for Neurodegenerative DiseasesAugust 26, 2025 | quiverquant.comQAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with BlarcamesineAugust 26, 2025 | globenewswire.comAnavex Life Sciences (NASDAQ:AVXL) Lowered to Sell Rating by Wall Street ZenAugust 25, 2025 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC WainwrightAugust 24, 2025 | marketbeat.comAnavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication ShowsAugust 20, 2025 | finance.yahoo.comAnavex Life Sciences Corp. Announces Positive Results for Blarcamesine in Preventing Cognitive Decline in Alzheimer's Disease ModelAugust 20, 2025 | quiverquant.comQ Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AVXL Media Mentions By Week AVXL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVXL News Sentiment▼0.510.77▲Average Medical News Sentiment AVXL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVXL Articles This Week▼105▲AVXL Articles Average Week Get the Latest News and Ratings for AVXL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Anavex Life Sciences and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AMRX News CNTA News XENE News CGON News APLS News IMVT News RARE News QURE News TARS News MOR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVXL) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
